礼来拟回购至多150亿美元股票并提高股息_老虎社区_美港股上老虎

礼来拟回购至多150亿美元股票并提高股息

智通财经12-10

礼来)周一批准了一项至多150亿美元的股票回购计划，并将季度股息提高了15%。受该消息影响，礼来股价盘后一度上涨1.3%。据悉，该公司的减肥和糖尿病药物大获成功，使其成为全球市值最高的制药公司。今年以来，礼来股价累计上涨39%。礼来早些时候宣布，在对比试验中，其减肥药物Zepbound的减重效果优于诺和诺德的Wegovy。试验显示，使用Zepbound的患者体重平均减轻20.2%，而Wegovy...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2490036299?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","is_english":false,"pubTime":"2024-12-10 13:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490036299","market":"us","top_or_hot":-1,"title":"礼来拟回购至多150亿美元股票并提高股息","media":"智通财经","content":"<div>\n<p>礼来)周一批准了一项至多150亿美元的股票回购计划，并将季度股息提高了15%。受该消息影响，礼来股价盘后一度上涨1.3%。据悉，该公司的减肥和糖尿病药物大获成功，使其成为全球市值最高的制药公司。今年以来，礼来股价累计上涨39%。礼来早些时候宣布，在对比试验中，其减肥药物Zepbound的减重效果优于诺和诺德的Wegovy。试验显示，使用Zepbound的患者体重平均减轻20.2%，而Wegovy...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1222539.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来拟回购至多150亿美元股票并提高股息</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来拟回购至多150亿美元股票并提高股息\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 13:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1222539.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>礼来)周一批准了一项至多150亿美元的股票回购计划，并将季度股息提高了15%。受该消息影响，礼来股价盘后一度上涨1.3%。据悉，该公司的减肥和糖尿病药物大获成功，使其成为全球市值最高的制药公司。今年以来，礼来股价累计上涨39%。礼来早些时候宣布，在对比试验中，其减肥药物Zepbound的减重效果优于诺和诺德的Wegovy。试验显示，使用Zepbound的患者体重平均减轻20.2%，而Wegovy...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1222539.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014906.USD","symbol_name":"大华全球优质成长基金Acc USD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1222539.html","article_id":"2490036299","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490036299","pubTimestamp":1733808202,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，礼来(LLY.US)周一批准了一项至多150亿美元的股票回购计划，并将季度股息提高了15%。受该消息影响，礼来股价盘后一度上涨1.3%。据悉，该公司的减肥和糖尿病药物大获成功，使其成为全球市值最高的制药公司。今年以来，礼来股价累计上涨39%。礼来早些时候宣布，在对比试验中，其减肥药物Zepbound的减重效果优于诺和诺德(NVO.US)的Wegovy。试验显示，使用Zepbound的患者体重平均减轻20.2%，而Wegovy患者体重减轻13.7%。礼来计划将结果发表在同行评审期刊，并在医学会议上发布。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999014906.USD":"大华全球优质成长基金Acc USD","SG9999001176.USD":"United Global Healthcare Acc USD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","BK4599":"减肥药","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","BK4585":"ETF&股票定投概念","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4007":"制药","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","BK4581":"高盛持仓","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LLY":"礼来","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD"},"translate_title":"Eli Lilly plans to buy back up to $15 billion in stock and raise Dividend","themeId":"739f0211dd84a2db1b92687969af47c9","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/235de1f149c28b69f55a26f43d1e0560","symbols_score_info":{"LLY":1},"content_text":"礼来)周一批准了一项至多150亿美元的股票回购计划，并将季度股息提高了15%。受该消息影响，礼来股价盘后一度上涨1.3%。据悉，该公司的减肥和糖尿病药物大获成功，使其成为全球市值最高的制药公司。今年以来，礼来股价累计上涨39%。礼来早些时候宣布，在对比试验中，其减肥药物Zepbound的减重效果优于诺和诺德的Wegovy。试验显示，使用Zepbound的患者体重平均减轻20.2%，而Wegovy患者体重减轻13.7%。礼来计划将结果发表在同行评审期刊，并在医学会议上发布。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}